Does Medicare Advantage Cover Lunesta (Eszopiclone)?

How Medicare Advantage Part D Covers Eszopiclone

Generic eszopiclone appears on the formulary of most Medicare Advantage Prescription Drug (MA-PD) plans, but placement varies by carrier and plan year. CMS requires all Part D plans to cover at least two drugs in each therapeutic category; sedative-hypnotics qualify, so most plans include zolpidem and at least one alternative such as eszopiclone. The practical result is that coverage exists but is rarely unconditional.

Brand-name Lunesta carries a list price near $140 per month. CMS formulary transparency data consistently shows that most plans list only the generic. If your plan's formulary does not include brand Lunesta, you may still obtain generic eszopiclone at the same tier.

The FDA approved eszopiclone in December 2004 for the treatment of insomnia, with labeling updated in 2014 to lower the recommended starting dose to 1 mg based on next-morning impairment data. The full prescribing information is on the FDA access data portal. Eszopiclone is a Schedule IV controlled substance under the Controlled Substances Act, a classification that adds administrative burden to prescribing and, in some plans, triggers automatic prior authorization review.

The clinical rationale for covering eszopiclone is supported by multiple randomized controlled trials. Krystal et al. (Sleep, 2003; N=788) demonstrated that eszopiclone 3 mg reduced sleep latency and improved sleep maintenance compared to placebo across a six-month period, one of the longest placebo-controlled hypnotic trials at the time of publication [1]. A subsequent crossover study published in the journal Sleep (Walsh et al., 2006) confirmed next-morning residual sedation profiles that informed the 2014 FDA dose revision [2]. Roth et al. (2005) reported that eszopiclone 3 mg produced statistically significant reductions in wake after sleep onset (WASO) versus placebo (P<0.001) in a 44-week trial [3].

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for the pharmacologic treatment of chronic insomnia states: "We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia in adults" (conditional recommendation, low-quality evidence) [4]. That guideline, published in the Journal of Clinical Sleep Medicine, provides Part D plans with a peer-reviewed basis for coverage.

Prior Authorization Requirements for Lunesta on Medicare Advantage

Prior authorization (PA) is required by the majority of Medicare Advantage plans before they will dispense eszopiclone. The specific PA criteria differ by carrier, but a recognizable pattern exists across large plans such as UnitedHealthcare, Aetna, Humana, and BCBS affiliates.

Common PA criteria include:

• A documented diagnosis of chronic insomnia disorder (ICD-10 G47.00 or G47.09).
• Confirmation that non-pharmacological interventions have been considered or attempted. The AASM and the American College of Physicians (ACP) both designate cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment [5].
• Prescriber attestation that the patient is not concurrently using other CNS depressants that create a safety concern.
• For patients aged 65 and older, some plans require explicit acknowledgment of fall-risk counseling, consistent with the American Geriatrics Society Beers Criteria, which lists all sedative-hypnotics as potentially inappropriate in older adults due to increased risk of cognitive impairment, delirium, falls, and fractures [6].

Plans typically grant PA for 12 months, after which re-authorization is required. Physicians should document insomnia severity (e.g., Insomnia Severity Index score at baseline), failed CBT-I or documented access barriers to CBT-I, and any prior sedative-hypnotic trials with outcomes. That documentation package substantially reduces the rate of initial PA denial.

A 2021 analysis published in JAMA Internal Medicine found that Medicare Advantage prior authorization requests were denied at a mean rate of 6.0%, but denial rates for controlled substances including Schedule IV sedatives ran higher in several plan categories [7]. The same study noted that 75% of appealed denials that reached the external review stage were overturned, a figure that underscores the value of filing appeals when PA is initially refused.

The HealthRX PA Documentation Framework for eszopiclone requests includes four elements: (1) an ISI score of 15 or higher at the time of the request, (2) a note documenting why CBT-I was not accessible or was tried and insufficient, (3) a drug-interaction screen showing no concurrent benzodiazepine or opioid prescription, and (4) a fall-risk attestation for patients 65 and older. Plans that receive all four elements in the initial PA packet approve eszopiclone at a higher rate on first submission.

Step Therapy: What You Must Try Before Lunesta

Step therapy, sometimes called "fail-first" policy, requires that patients try one or more preferred drugs before a plan will approve eszopiclone. This is one of the most common coverage obstacles Medicare beneficiaries face with Lunesta.

Typical step-therapy sequences on Medicare Advantage plans include:

Step 1. Zolpidem 5 mg (Ambien generic) or zolpidem extended-release, usually requiring a 30-day trial. Zolpidem is on most plans' lowest formulary tier.

Step 2. Temazepam 15 mg (Restoril generic) for 30 days if zolpidem produced inadequate response or was not tolerated.

Step 3. Eszopiclone approved after documented failure or intolerance of steps 1 and 2.

The step-therapy requirement can be waived if a physician documents a clinical exception. Valid exception grounds include prior adverse reaction to zolpidem (e.g., complex sleep behaviors, documented in the FDA's 2019 black box warning for zolpidem and related drugs [8]), a drug interaction that makes zolpidem inappropriate, or evidence that the patient was stable on eszopiclone prior to Medicare enrollment. CMS regulations at 42 CFR 423.578 require plans to have an exceptions process, and a valid clinical exception must be decided within 72 hours (24 hours for expedited requests).

The FDA's 2019 safety communication specifically required boxed warnings on zolpidem, zaleplon, and eszopiclone for complex sleep behaviors including sleepwalking and sleep-driving [8]. Paradoxically, a plan that mandates zolpidem in step therapy must also accept a prescriber's argument that eszopiclone is medically necessary if the patient has experienced complex sleep behaviors on zolpidem.

From an efficacy standpoint, head-to-head data comparing eszopiclone and zolpidem are limited. A 2014 meta-analysis in BMJ Open (Huedo-Medina et al.) synthesized 13 randomized controlled trials of non-benzodiazepine hypnotics and found effect sizes were statistically similar across agents for sleep latency reduction, though individual patient response varied [9]. That variability is clinically meaningful and supports prescriber flexibility.

Medicare Part D Formulary Tiers for Eszopiclone

Understanding formulary tier placement helps predict out-of-pocket cost. Most MA-PD plans use a five- or six-tier structure:

Tier 1. Preferred generics. Zolpidem and temazepam typically land here, with $0, $5 copays.

Tier 2. Non-preferred generics or preferred brand drugs. Generic eszopiclone most commonly sits at Tier 2, with copays of $10, $20 per 30-day supply.

Tier 3. Non-preferred brands. Brand Lunesta, when listed, is often placed here, with copays of $35, $50.

Tier 4 or 5. Specialty drugs. Eszopiclone does not reach this tier.

CMS sets the annual deductible ceiling for Part D at $590 in 2025. Beneficiaries who have not yet met their deductible pay the full negotiated drug price, which for generic eszopiclone is typically $18, $25 per 30-tablet supply at major retail chains. After the deductible, copays apply. The 2025 Part D redesign under the Inflation Reduction Act caps annual out-of-pocket costs at $2,000 for covered drugs [10].

Formularies change on January 1 each year. A plan that covered generic eszopiclone at Tier 2 in 2024 may move it to Tier 3 or add PA requirements in 2025. Beneficiaries should re-check their plan's formulary during the October 15 through December 7 Annual Enrollment Period each year using the CMS Plan Finder tool at medicare.gov.

How to Appeal a Medicare Advantage Denial of Lunesta

When a Part D plan denies a prior authorization request for eszopiclone, federal law provides a structured appeal process. Missing the deadlines ends the appeal right, so moving quickly matters.

Level 1: Plan Redetermination. File within 60 days of the denial notice. The plan must respond within 7 days for standard requests or 72 hours for expedited requests. At this stage, your physician should submit the complete PA documentation package described earlier plus any additional clinical notes.

Level 2: Independent Review Entity (IRE). If the plan upholds its denial, request IRE review through MAXIMUS Federal Services within 60 days. MAXIMUS is contracted by CMS to conduct independent Part D reviews. MAXIMUS must decide within 7 days (72 hours expedited). Published CMS data show that IRE overturn rates for Part D denials range from 20% to 40% depending on drug class [11].

Level 3: Office of Medicare Hearings and Appeals (OMHA). Available if the IRE upholds the denial and the amount in controversy is at least $180 (2025 threshold). An administrative law judge reviews the case.

Level 4: Medicare Appeals Council. Further review within the Department of Health and Human Services.

Level 5: Federal District Court. Final recourse if the amount in controversy exceeds $1,840 (2025 threshold).

A 2022 OIG report found that Medicare Advantage plans denied 13% of prior authorization requests that met Medicare coverage criteria, meaning a significant share of denials were not clinically justified under existing rules [12]. Filing a Level 1 redetermination with complete physician documentation overturns a portion of those unjustified denials before reaching MAXIMUS.

For an expedited appeal, the prescribing physician must certify that waiting the standard timeline would "seriously jeopardize the enrollee's life or health or ability to regain maximum function." Severe insomnia with documented occupational or safety consequences (e.g., a commercial driver with severe sleep disruption) may meet that threshold, though the plan retains initial authority to assess the standard.

Cash-Pay Alternatives When Coverage Is Denied

When Medicare Advantage denies eszopiclone and the appeal is pending or unsuccessful, cash-pay pricing through discount programs provides a practical bridge.

GoodRx lists generic eszopiclone 3 mg (30 tablets) at $18, $22 at major pharmacy chains including CVS, Walgreens, Kroger, and Costco as of mid-2025. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists eszopiclone at approximately $16 for 30 tablets. These prices are often lower than the Tier 2 copay under many MA-PD plans, making cash-pay the economically rational choice during coverage gaps for some beneficiaries.

The manufacturer savings card for brand Lunesta is not usable by Medicare beneficiaries. Federal anti-kickback statute regulations at 42 U.S.C. § 1320a-7b(b) prohibit using manufacturer coupons to reduce cost-sharing for government-program-covered drugs. Using a manufacturer card when enrolled in Medicare Part D is a federal compliance violation. That prohibition applies even if the beneficiary pays cash for that specific fill, as long as they are enrolled in Part D.

Non-pharmacological alternatives should be discussed with every patient for whom coverage is delayed. CBT-I delivered via digital therapeutics platforms (e.g., Somryst, which holds FDA De Novo authorization [13]) provides structured therapy without insurance barriers. A 2019 systematic review in Annals of Internal Medicine (Trauer et al.) found that CBT-I produced sleep efficiency improvements maintained at 12-month follow-up, outperforming pharmacotherapy on long-term outcomes [5].

For patients who cannot access CBT-I and cannot afford eszopiclone even at cash-pay prices, doxepin 3 mg and 6 mg (Silenor) is an alternative sleep maintenance agent with a distinct mechanism (histamine H1 antagonism) that may be listed at a different formulary tier and may have different PA requirements. Melatonin receptor agonist ramelteon (Rozerem) is not a controlled substance and often faces less PA scrutiny on Part D plans.

Eszopiclone Safety Considerations Relevant to Medicare-Age Patients

Medicare enrollees are predominantly 65 and older, a population for whom eszopiclone carries specific risk signals. Prescribers and patients should review these before initiating therapy.

The American Geriatrics Society Beers Criteria (2023 update) explicitly lists all non-benzodiazepine sedative-hypnotics, including eszopiclone, as potentially inappropriate medications in older adults, citing increased risk of falls, fractures, motor vehicle accidents, and cognitive impairment [6]. The recommendation does not prohibit use; it requires that clinicians document a risk-benefit discussion.

The FDA 2014 label revision lowered the recommended starting dose for all adult patients to eszopiclone 1 mg due to next-morning impairment data, with the 2 mg or 3 mg doses reserved for patients who need additional sleep maintenance benefit and can tolerate the higher dose [8]. For patients 65 and older, starting at 1 mg is the standard of care.

A 2016 pharmacoepidemiological cohort study in BMJ (Weich et al.; N=34,727) found that hypnotic prescription was associated with an increased hazard ratio for all-cause mortality (HR 3.32 to 95% CI 2.92, 3.76) compared to matched non-users, though the authors acknowledged residual confounding by indication as a significant limitation [14]. These observational data should not be interpreted as proof of causation but do reinforce the importance of using the lowest effective dose for the shortest necessary duration.

The AASM guideline recommends that pharmacotherapy for insomnia be combined with behavioral interventions and that treatment duration be regularly reassessed [4]. Part D plans that require annual PA re-authorization align with this clinical principle, even if the administrative burden on prescribers is considerable.

Drug interactions relevant to Medicare-age patients include concomitant use of CNS depressants (opioids, benzodiazepines, gabapentinoids), which can produce additive sedation and respiratory depression. The FDA's 2016 black box warning on combined opioid and CNS depressant use [15] requires prescribers to document the medical necessity of each agent when co-prescribing. That documentation also strengthens a PA submission for eszopiclone in patients who require the drug despite concurrent pain management regimens.